Tempus AI: Initiation Of Coverage – Expansion in Minimal Residual Disease (MRD) Testing & 4 Other Factors That Could Shape Its Future! 

Tempus AI reported its third-quarter 2024 financial results, reflecting positive revenue growth but continuing to face profitability challenges. Revenue rose by 33%, reaching $180.9 million, driven by growth in the Genomics and Data and Services segments. Notably, the Genomics unit growth accelerated to 23.9%, which shows a significant uptick from the previous quarter. The Data and Services revenue surged by 64.4% year-over-year, propelled by the insights and data licensing business with an 86.6% increase, highlighting strong market interest and demand for Tempus’s data offerings.